id: np_pa_prescribing_authority_to_rural_mat_treatment_capacity
name: Nurse Practitioner and Physician Assistant Prescribing Authority for Buprenorphine
  â†’ Rural Medication-Assisted Treatment Capacity
from_node:
  node_id: np_pa_prescribing_authority
  node_name: Nurse Practitioner and Physician Assistant Prescribing Authority for
    Buprenorphine
to_node:
  node_id: rural_mat_treatment_capacity
  node_name: Rural Medication-Assisted Treatment Capacity
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: The Comprehensive Addiction and Recovery Act grants DEA waiver authority
  to NPs and PAs to prescribe buprenorphine for opioid use disorder'
- 'Step 2: NPs and PAs are more geographically distributed in rural areas than waivered
  physicians'
- 'Step 3: Expanded prescriber pool increases the number of available treatment slots
  in rural communities'
- 'Step 4: Increased treatment slot availability reduces geographic barriers to accessing
  medication-assisted treatment for rural patients with opioid use disorder'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: C. H. A. Andrilla et al. 2018. "Projected Contributions of Nurse
    Practitioners and Physicians Assistant to Buprenorphine Treatment Services for
    Opioid Use Disorder in Rural Areas." *Medical Care Research and Review*. https://doi.org/10.1177/1077558718793070
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:07.480366'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: census_division_geographic_location
  direction: strengthens
  strength: strong
  description: Geographic location by Census Division substantially moderates the
    impact, with New England and East South Central regions experiencing the largest
    population-adjusted increases in treatment capacity
- name: state_scope_of_practice_regulations
  direction: strengthens
  strength: strong
  description: State-level scope of practice regulations for NPs and PAs determine
    whether and how these providers can prescribe buprenorphine, creating interstate
    variation in treatment capacity expansion
